| Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy J Deng, A Paulus, DD Fang, A Manna, G Wang, H Wang, S Zhu, J Chen, ... Clinical Cancer Research 28 (24), 5455-5468, 2022 | 17 | 2022 |
